Technology Transfer Company (Yissum)

Technology Transfer Company (Yissum)
Name	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Native name	ייסוד מחקר ופיתוח של האוניברסיטה העברית בירושלים בע"מ
Founded	1964
Founder	Hebrew University of Jerusalem
Headquarters	Jerusalem
Key people	Prof. Chaim Elata; Dr. Arie Belldegrun; Dr. Rafi Beyar
Products	Biotechnology; Pharmaceutical industry; Nanotechnology; Agricultural biotechnology
Services	Technology transfer; Intellectual property management; Venture creation
Owner	Hebrew University of Jerusalem

Technology Transfer Company (Yissum)

Founded in 1964 by the Hebrew University of Jerusalem, the company serves as the university’s technology commercialization arm, managing inventions, patents, licensing, and start-up creation. It operates at the nexus of academic research and industry commercialization, engaging with multinational corporations, venture capital firms, and entrepreneurial ecosystems to translate laboratory discoveries into marketable products. Over decades the organization influenced sectors including biotechnology, agriculture, information technology, and materials science through a portfolio of patents and spin-off companies.

History

Established in the mid-20th century amid global growth of university-based technology transfer models, the company was created shortly after the passage of national and international legal frameworks that encouraged academic commercialization. It mirrored structures seen at institutions like Stanford University, Massachusetts Institute of Technology, and University of Oxford, while operating within the Israeli innovation environment shaped by entities such as Israel Innovation Authority and the rise of the Tel Aviv Stock Exchange. Early milestones include licensing agreements in agricultural research related to Dr. Aaron Ciechanover-era biotechnology advances and later commercialization of medical devices influenced by collaborations with hospitals such as Hadassah Medical Center and Shaare Zedek Medical Center.

Mission and Activities

The company’s stated mission emphasizes protecting intellectual property, creating start-ups, and licensing technologies developed at the Hebrew University of Jerusalem. Core activities include patent filing, technology assessment, market analysis, and negotiation with firms like Teva Pharmaceutical Industries, Johnson & Johnson, and Pfizer. It facilitates entrepreneurship through incubators and venture creation programs similar to Yozma-era initiatives and cooperates with investors including Sequoia Capital, aMoon Capital, and regional accelerators. The organization supports translational pathways spanning bench-to-bedside and field deployment, interfacing with research groups such as those led by Prof. Ada Yonath and Prof. Menachem Friedman.

Organizational Structure and Governance

Operated as a wholly owned subsidiary of Hebrew University of Jerusalem, governance includes a board with university appointees, legal counsel, patent managers, and technology scouts. Executive leadership coordinates with academic departments like Faculty of Medicine, The Institute of Life Sciences, and the School of Pharmacy. The structure resembles technology transfer offices at Columbia University and University of Cambridge, integrating business development officers, licensing executives, and spin-off incubators. Oversight mechanisms involve compliance with Israeli and international patent regimes such as the European Patent Convention and engagement with law firms and patent offices in jurisdictions including United States Patent and Trademark Office and World Intellectual Property Organization.

Major Innovations and Contributions

The company has been associated with commercially successful technologies spanning pharmaceuticals, diagnostics, agricultural strains, and software. Notable outputs include licensed therapeutics and diagnostics informed by Nobel-linked research such as that of Prof. Avram Hershko and Prof. Dan Shechtman, medical devices that reached markets through partners like Medtronic and Boston Scientific, and agricultural innovations tied to institutes like Volcani Center. Its spin-offs have addressed global challenges in infectious disease, oncology, neurodegeneration, and sustainable agriculture while engaging with international initiatives including collaborations with World Health Organization projects and multinational research consortia.

Intellectual Property and Licensing Practices

Patent management emphasizes securing priority filings globally, prosecuting patents through international patent families, and crafting license agreements ranging from exclusive commercialization rights to field-limited, territory-specific licenses. The office negotiates royalty streams, milestone payments, and equity stakes in start-ups, working with investors such as Pitango Venture Capital and legal advisors experienced with Bayh–Dole Act-style frameworks. Technology transfer practices follow benchmarking against peer institutions like University of California system offices, emphasizing conflict-of-interest policies and material transfer agreements consistent with standards used by entities like Howard Hughes Medical Institute.

Partnerships and Industry Collaborations

Collaborations span multinational corporations, start-up investors, government programs, and international universities including Harvard University, University of Oxford, and Technion – Israel Institute of Technology. Joint ventures, research collaborations, and co-development agreements have linked the company with pharmaceutical firms such as Roche and Novartis, agri-tech companies like Syngenta, and technology firms including Google and Intel. Participation in European Framework Programs and bilateral agreements with research councils has enabled cross-border development and co-funding of translational projects.

Impact, Economic Outcomes, and Spin-offs

Economic output includes licensing revenue, equity realizations from exits, and job creation through spin-offs that have listed on exchanges such as the Nasdaq and Tel Aviv Stock Exchange. Successful exits and growth stories resemble those of Israeli start-ups like Mobileye and Wix.com in demonstrating university-originated commercialization pathways. The cumulative impact extends to regional innovation clusters in Jerusalem and national contributions to Israel’s reputation as a "Start-up Nation," fostering entrepreneurship among alumni, researchers, and external investors.

Criticisms and Controversies

Critiques include debates over university commercialization priorities, allocation of revenue between inventors and the parent institution, and potential conflicts between academic openness and proprietary protection—issues echoed in discussions involving Academy of Sciences-style bodies and legislative frameworks. Controversial licensing decisions and equity holdings in start-ups have prompted scrutiny from stakeholders including research communities and policy analysts, paralleling controversies seen at institutions like University of California and Imperial College London.

Category:Technology transfer offices Category:Hebrew University of Jerusalem